^
Association details:
| Biomarker: | CD20 positive |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Regimen: | FCR (cyclophosphamide + fludarabine IV + Rituxan (rituximab)) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia
Published date:
11/27/2020
Excerpt:
We investigated the efficacy and safety of FCR in this single-arm, multicenter study designed as a bridging study to the CLL8 study by the German CLL Study Group....Although the number of patients was limited, FCR appears to be effective with manageable toxicity for treatment-naïve fit Japanese patients with CD20-positive CLL.
DOI:
10.1093/jjco/hyaa215
